Amira Pharmaceuticals is a small molecule pharmaceutical company founded in 2005, specializing in the discovery and early development of new drugs for inflammatory diseases. The company's focus lies in leveraging insights into bioactive lipid pathways and complex signaling processes to address various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular, and fibrotic diseases.
The most recent funding round for Amira Pharmaceuticals was a $25.00M Series B investment on 23 March 2007. This investment was led by prominent venture capital firms Novo Holdings, Avalon Ventures, Prospect Venture Partners, and Versant Ventures.
Specializing in the biotechnology, healthcare, and pharmaceutical industries, Amira Pharmaceuticals holds promise in addressing critical unmet medical needs. With a strong portfolio of potential treatments, the company presents an exciting opportunity for venture capitalists looking to invest in innovative solutions for inflammatory diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $25.00M | 4 |
|
23 Mar 2007 |
| Series A | $4.00M | 3 |
|
01 Nov 2006 |
| Series A | $3.00M | 3 |
|
10 Aug 2005 |
No recent news or press coverage available for Amira Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.